Theresa <span>Ann</span> Boyle
Researcher

Theresa Ann Boyle

Overview

Dr. Boyle's clinical work focuses on interpretation of molecular results to guide patient therapy. She also acts as a consult for both physicians and patients to improve their understanding of molecular results.

Discipline

    • Anatomic Pathology
    • Tumor Biology
    • Chemical Biology and Molecular Medicine Program

Education & Training

    • Howard University College of Medicine, MD
    • University of Colorado Health Sciences Center, PhD - Human Medical Genetics
    • University of Colorado at Denver, Resident - Clinical and Anatomic Pathology
    • Stanford University, Palo Alto, Fellow - Molecular Genetic Patholoy
Research

Research Interests: To develop assays, such as the proximity ligation assay (PLA) to visualize cancer signaling pathway response to drug therapy. To investigate tumor biomarkers that predicts response to therapy, such as those that identify patients with tumors that will most likely to respond to immunotherapy. To develop resources, such as tumor microarrays (TMAs), to facilitate research and clinical assay development.

Publications

  • Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. J Thorac Oncol. 2017 Jan;12(1):110-120. Pubmedid: 27639678. Pmcid: PMC5353355.
  • Yu H, Boyle TA, Zhou C, Rimm D, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016 Jul;11(7):964-975. Pubmedid: 27117833. Pmcid: PMC5353357.
  • Bishop AC, Boyle TA. The Role of Safety Culture in Influencing Provider Perceptions of Patient Safety. J Patient Saf. 2016 Dec;12(4):204-209. Pubmedid: 24618647.
  • Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015 Mar;16(2):106-111. Pubmedid: 25467930. Pmcid: PMC4770803.
  • Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar;20(3):316-322. Pubmedid: 25721120. Pmcid: PMC4350802.
  • Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):1083-1090. Pubmedid: 26020126. Pmcid: PMC4467588.
  • Bishop AC, Baker GR, Boyle TA, MacKinnon NJ. Using the Health Belief Model to explain patient involvement in patient safety. Health Expect. 2015 Dec;18(6):3019-3033. Pubmedid: 25303173.
  • Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014 Mar;9(3):e21-e23. Pubmedid: 24518095. Pmcid: PMC4117236.
  • Aherne CM, Collins CB, Masterson JC, Tizzano M, Boyle TA, Westrich JA, Parnes JA, Furuta GT, Rivera-Nieves J, Eltzschig HK. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut. 2012 May;61(5):695-705. Pubmedid: 21813473. Pmcid: PMC3322588.
  • Baschal EE, Jasinski JM, Boyle TA, Fain PR, Eisenbarth GS, Siebert JC. Congruence as a measurement of extended haplotype structure across the genome. J Transl Med. 2012 Feb;10:32. Pubmedid: 22369243. Pmcid: PMC3310717.
  • Baschal EE, Sarkar SA, Boyle TA, Siebert JC, Jasinski JM, Grabek KR, Armstrong TK, Babu SR, Fain PR, Steck AK, Rewers MJ, Eisenbarth GS. Replication and further characterization of a Type 1 diabetes-associated locus at the telomeric end of the major histocompatibility complex. J Diabetes. 2011 Sep;3(3):238-247. Pubmedid: 21631897. Pmcid: PMC3610173.
  • Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 2011 Mar;71(6):2087-2097. Pubmedid: 21335545. Pmcid: PMC3271733.